Do analysts recommend ABC or ONT?

Oxford Nanopore Technologies has a consensus price target of GBX 218.60, indicating a potential upside of 90.58%. Given Oxford Nanopore Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Oxford Nanopore Technologies is more favorable than Abcam. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abcam 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Oxford Nanopore Technologies 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80

Do analysts recommend SLN or ONT?

Oxford Nanopore Technologies has a consensus price target of GBX 218.60, indicating a potential upside of 90.58%. Given Oxford Nanopore Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Oxford Nanopore Technologies is more favorable than Silence Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Oxford Nanopore Technologies 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80

Oxford Nanopore Technologies (ONT) Competitors

GBX 114.70 +1.50 (+1.33%)

As of 12:14 PM Eastern

Compare

ONT vs. ABC, GNS, OXB, ERGO, and SLN

Should you buy Oxford Nanopore Technologies stock or one of its competitors? MarketBeat compares Oxford Nanopore Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oxford Nanopore Technologies include Abcam (ABC), Genus (GNS), Oxford Biomedica (OXB), Ergomed (ERGO), and Silence Therapeutics (SLN). These companies are all part of the "biotechnology" industry.

How does Oxford Nanopore Technologies compare to Abcam?

Abcam (LON:ABC) and Oxford Nanopore Technologies (LON:ONT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

In the previous week, Oxford Nanopore Technologies' average media sentiment score of 1.26 beat Abcam's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Abcam	Neutral
Oxford Nanopore Technologies	Positive

Abcam has a net margin of 0.00% compared to Oxford Nanopore Technologies' net margin of -64.85%. Abcam's return on equity of 0.00% beat Oxford Nanopore Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abcam	N/A	N/A	N/A
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%

Oxford Nanopore Technologies has a consensus price target of GBX 218.60, indicating a potential upside of 90.58%. Given Oxford Nanopore Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Oxford Nanopore Technologies is more favorable than Abcam.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abcam	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Abcam has higher revenue and earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Abcam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abcam	£350.40M	0.00	N/A	£0.06	N/A
Oxford Nanopore Technologies	£223.90M	4.98	-£175.21M	-£15.10	N/A

19.6% of Oxford Nanopore Technologies shares are held by institutional investors. 2.5% of Oxford Nanopore Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Abcam and Oxford Nanopore Technologies tied by winning 6 of the 12 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Genus?

Genus (LON:GNS) and Oxford Nanopore Technologies (LON:ONT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

52.9% of Genus shares are owned by institutional investors. Comparatively, 19.6% of Oxford Nanopore Technologies shares are owned by institutional investors. 0.7% of Genus shares are owned by company insiders. Comparatively, 2.5% of Oxford Nanopore Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Genus has a beta of 0.896, meaning that its share price is 10% less volatile than the broader market. Comparatively, Oxford Nanopore Technologies has a beta of 0.914, meaning that its share price is 9% less volatile than the broader market.

In the previous week, Oxford Nanopore Technologies' average media sentiment score of 1.26 beat Genus' score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Genus	Neutral
Oxford Nanopore Technologies	Positive

Genus currently has a consensus price target of GBX 3,216.67, suggesting a potential upside of 52.45%. Oxford Nanopore Technologies has a consensus price target of GBX 218.60, suggesting a potential upside of 90.58%. Given Oxford Nanopore Technologies' higher possible upside, analysts clearly believe Oxford Nanopore Technologies is more favorable than Genus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Genus has higher revenue and earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£672M	2.09	£7.87M	£71.00	29.72
Oxford Nanopore Technologies	£223.90M	4.98	-£175.21M	-£15.10	N/A

Genus has a net margin of 7.07% compared to Oxford Nanopore Technologies' net margin of -64.85%. Genus' return on equity of 9.70% beat Oxford Nanopore Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	7.07%	9.70%	3.31%
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%

Summary

Genus beats Oxford Nanopore Technologies on 9 of the 15 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Oxford Biomedica?

Oxford Nanopore Technologies (LON:ONT) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

Oxford Nanopore Technologies has a beta of 0.914, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.096, suggesting that its share price is 10% more volatile than the broader market.

Oxford Biomedica has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Biomedica is trading at a lower price-to-earnings ratio than Oxford Nanopore Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Nanopore Technologies	£223.90M	4.98	-£175.21M	-£15.10	N/A
Oxford Biomedica	£168.74M	4.30	-£143.51M	-£26.92	N/A

Oxford Biomedica has a net margin of -17.85% compared to Oxford Nanopore Technologies' net margin of -64.85%. Oxford Nanopore Technologies' return on equity of -29.43% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%
Oxford Biomedica	-17.85%	-48.56%	-12.67%

19.6% of Oxford Nanopore Technologies shares are held by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are held by institutional investors. 2.5% of Oxford Nanopore Technologies shares are held by insiders. Comparatively, 43.3% of Oxford Biomedica shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Oxford Nanopore Technologies currently has a consensus price target of GBX 218.60, indicating a potential upside of 90.58%. Oxford Biomedica has a consensus price target of GBX 604.32, indicating a potential upside of 0.72%. Given Oxford Nanopore Technologies' higher probable upside, equities analysts plainly believe Oxford Nanopore Technologies is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

In the previous week, Oxford Biomedica had 3 more articles in the media than Oxford Nanopore Technologies. MarketBeat recorded 3 mentions for Oxford Biomedica and 0 mentions for Oxford Nanopore Technologies. Oxford Nanopore Technologies' average media sentiment score of 1.26 beat Oxford Biomedica's score of 0.38 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Oxford Nanopore Technologies	Positive
Oxford Biomedica	Neutral

Summary

Oxford Biomedica beats Oxford Nanopore Technologies on 9 of the 16 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Ergomed?

Oxford Nanopore Technologies (LON:ONT) and Ergomed (LON:ERGO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Oxford Nanopore Technologies has a beta of 0.914, meaning that its share price is 9% less volatile than the broader market. Comparatively, Ergomed has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

Ergomed has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Nanopore Technologies	£223.90M	4.98	-£175.21M	-£15.10	N/A
Ergomed	£152.09M	0.00	£15M	£0.29	N/A

In the previous week, Oxford Nanopore Technologies' average media sentiment score of 1.26 beat Ergomed's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Oxford Nanopore Technologies	Positive
Ergomed	Neutral

19.6% of Oxford Nanopore Technologies shares are owned by institutional investors. Comparatively, 71.1% of Ergomed shares are owned by institutional investors. 2.5% of Oxford Nanopore Technologies shares are owned by insiders. Comparatively, 18.2% of Ergomed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Ergomed has a net margin of 9.87% compared to Oxford Nanopore Technologies' net margin of -64.85%. Ergomed's return on equity of 18.08% beat Oxford Nanopore Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%
Ergomed	9.87%	18.08%	10.16%

Oxford Nanopore Technologies currently has a consensus price target of GBX 218.60, indicating a potential upside of 90.58%. Given Oxford Nanopore Technologies' stronger consensus rating and higher probable upside, equities research analysts plainly believe Oxford Nanopore Technologies is more favorable than Ergomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Ergomed	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Ergomed beats Oxford Nanopore Technologies on 8 of the 14 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Silence Therapeutics?

Silence Therapeutics (LON:SLN) and Oxford Nanopore Technologies (LON:ONT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

19.6% of Oxford Nanopore Technologies shares are held by institutional investors. 2.5% of Oxford Nanopore Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Oxford Nanopore Technologies has a consensus price target of GBX 218.60, indicating a potential upside of 90.58%. Given Oxford Nanopore Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Oxford Nanopore Technologies is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Silence Therapeutics had 1 more articles in the media than Oxford Nanopore Technologies. MarketBeat recorded 1 mentions for Silence Therapeutics and 0 mentions for Oxford Nanopore Technologies. Oxford Nanopore Technologies' average media sentiment score of 1.26 beat Silence Therapeutics' score of -0.77 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Silence Therapeutics	Negative
Oxford Nanopore Technologies	Positive

Silence Therapeutics has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A
Oxford Nanopore Technologies	£223.90M	4.98	-£175.21M	-£15.10	N/A

Silence Therapeutics has a net margin of 0.00% compared to Oxford Nanopore Technologies' net margin of -64.85%. Silence Therapeutics' return on equity of 0.00% beat Oxford Nanopore Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	N/A	N/A	N/A
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%

Summary

Oxford Nanopore Technologies beats Silence Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Oxford Nanopore Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONT vs. The Competition

Export

Metric	Oxford Nanopore Technologies	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£1.12B	£474.43M	£6.45B	£2.78B
Dividend Yield	N/A	3.86%	2.69%	6.16%
P/E Ratio	-7.60	3.12	21.07	365.72
Price / Sales	4.98	6,492.01	530.36	86,253.69
Price / Cash	4.04	13.13	44.82	27.85
Price / Book	1.71	91.17	10.79	7.92
Net Income	-£175.21M	-£96.07M	£3.56B	£5.89B
7 Day Performance	-2.43%	1.69%	1.67%	-0.87%
1 Month Performance	-11.74%	0.77%	0.43%	-0.76%
1 Year Performance	-7.72%	64.35%	32.84%	70.67%

Oxford Nanopore Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONT Oxford Nanopore Technologies	2.6475 of 5 stars	GBX 114.70 +1.3%	GBX 218.60 +90.6%	-4.9%	£1.12B	£223.90M	N/A	1,281	Positive News
ABC Abcam	N/A	N/A	N/A	N/A	£2.81B	£350.40M	20,433.33	1,650	Gap Up High Trading Volume
GNS Genus	2.4798 of 5 stars	GBX 2,216 +1.7%	GBX 3,216.67 +45.2%	+11.0%	£1.47B	£672M	31.21	480	High Trading Volume
OXB Oxford Biomedica	1.1954 of 5 stars	GBX 601 -0.5%	GBX 604.32 +0.6%	+86.3%	£727.26M	£168.74M	N/A	891	News Coverage Gap Up
ERGO Ergomed	N/A	N/A	N/A	N/A	£701.00M	£152.09M	4,641.38	6

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:ONT) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oxford Nanopore Technologies (ONT) Competitors

ONT vs. ABC, GNS, OXB, ERGO, and SLN

How does Oxford Nanopore Technologies compare to Abcam?

Summary

How does Oxford Nanopore Technologies compare to Genus?

Summary

How does Oxford Nanopore Technologies compare to Oxford Biomedica?

Summary

How does Oxford Nanopore Technologies compare to Ergomed?

Summary

How does Oxford Nanopore Technologies compare to Silence Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONT vs. The Competition

Oxford Nanopore Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oxford Nanopore Technologies (ONT) Competitors

ONT vs. ABC, GNS, OXB, ERGO, and SLN

How does Oxford Nanopore Technologies compare to Abcam?

Does the media prefer ABC or ONT?

Is ABC or ONT more profitable?

Do analysts recommend ABC or ONT?

Which has stronger earnings & valuation, ABC or ONT?

Do insiders and institutionals believe in ABC or ONT?

Summary

How does Oxford Nanopore Technologies compare to Genus?

Do insiders and institutionals hold more shares of GNS or ONT?

Which has more risk and volatility, GNS or ONT?

Does the media refer more to GNS or ONT?

Do analysts recommend GNS or ONT?

Which has higher earnings and valuation, GNS or ONT?

Is GNS or ONT more profitable?

Summary

How does Oxford Nanopore Technologies compare to Oxford Biomedica?

Which has more risk & volatility, ONT or OXB?

Which has higher valuation & earnings, ONT or OXB?

Is ONT or OXB more profitable?

Do institutionals and insiders hold more shares of ONT or OXB?

Do analysts recommend ONT or OXB?

Does the media favor ONT or OXB?

Summary

How does Oxford Nanopore Technologies compare to Ergomed?

Which has more risk & volatility, ONT or ERGO?

Which has higher earnings and valuation, ONT or ERGO?

Does the media prefer ONT or ERGO?

Do insiders & institutionals have more ownership in ONT or ERGO?

Is ONT or ERGO more profitable?

Do analysts rate ONT or ERGO?

Summary

How does Oxford Nanopore Technologies compare to Silence Therapeutics?

Do insiders & institutionals hold more shares of SLN or ONT?

Do analysts recommend SLN or ONT?

Does the media prefer SLN or ONT?

Which has better valuation and earnings, SLN or ONT?

Is SLN or ONT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONT vs. The Competition

Oxford Nanopore Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools